The new standard for biochemicals
Drop-in. Cost-competitive. Proven hardware. Industrial scale. Available locally. Deployable globally.
What we do
Biosimo converts bioethanol into platform chemicals using a proprietary catalyst in a single continuous step. Standard reactor. Standard feedstock. No first-of-a-kind hardware. Our flagship product is bio-acetic acid. We are expanding into acetaldehyde, ethyl acetate, and bio-VAM.
Four ethanol sources from two continents validated. No feedstock-specific redesign. Geographic resilience built in.
Proprietary catalytic process. Lower energy input. Designed to compete at fossil economics — not dependent on green premiums or subsidies.
8,000+ hours stable catalyst operation. No first-of-a-kind hardware. Standard fixed-bed reactor, extraction, distillation. Built to run on existing infrastructure.
Bio-acetic acid available now. Bio-acetaldehyde, ethyl acetate, bio-VAM, and other acetyls on demand. Every product driven by customer demand.
How it works
One step. Bioethanol plus air enters a standard fixed-bed reactor with our proprietary catalyst. Out comes bio-acetic acid.
Our technology is based on the oxidation of bioethanol with the help of the Biosimo heterogeneous catalyst in continuous flow.
Products
Primary and Resource-Based Industries
Agriculture
Oil
Gas
Mining
Manufacturing and Industrial
Automotive & Transportive
Building & Construction
Consumer Goods and Services
Home Care I&I
Cosmetics
Personal Care
About us
ETH Zurich spin-off. Founded in 2022. Zurich and Houston. Built with customers from day one. Hundred customer engagements. 30+ interviews. 5 purchase orders delivered, paid samples shipped, and qualified from two of the top three acetyls producers globally. $1.4M raised, ~$1M in grants. Pilot to kiloton expected in 2027.
Supported by
